Related references
Note: Only part of the references are listed.Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey
Tara Cusick et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib
Thomas M. Ruenger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys
C. Jerome et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Safety and Efficacy of the Cathepsin K Inhibitor ONO-5334 in Postmenopausal Osteoporosis: The OCEAN Study
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Heterogeneity of human bone
James T. Ninomiya et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Long-Term Use of Bisphosphonates in Osteoporosis
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
S. A. Stoch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Bisphosphonate-associated adverse events
Peter D. Papapetrou
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Potential new drug targets for osteoporosis
Chad Deal
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2009)
Drug-induced morphea: Report of a case induced by balicatib and review of the literature
Anna Peroni et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution
S.-K. Goh et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2007)
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys
S. Kumar et al.
BONE (2007)
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies
S Boonen et al.
OSTEOPOROSIS INTERNATIONAL (2005)
The role of cathepsins in osteoporosis and arthritis:: Rationale for the design of new therapeutics
Y Yasuda et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
Peter Pietschmann
JOURNAL FUR MINERALSTOFFWECHSEL (2005)
Share Paper
